Alnylam Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-490.9M | $-410.1M | $-290.1M | $-360.4M | $-89.2M | $-106.0M | $-57.6M | $-43.5M |
| Depreciation & Amortization | $13.4M | $15.1M | $19.1M | $11.9M | $10.2M | $9.0M | $5.1M | $4.9M |
| Depreciation | $11.9M | $9.6M | $6.7M | $5.0M | $6.1M | $4.6M | $5.0M | $4.8M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $92.8M | $75.5M | $45.8M | $33.1M | $20.7M | $12.4M | $16.7M | $19.1M |
| Net Cash from Operating Activities | $-382.8M | $-307.7M | $-189.1M | $-165.6M | $-68.7M | $-115.6M | $-87.1M | $-84.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $104.2M | $64.6M | $13.0M | $9.0M | $4.0M | $8.3M | $1.3M | $4.7M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-290.4M | $142.6M | — | — | $-130.5M | $3.4M | $82.0M | $17.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.12B | $177.8M | — | — | $200.9M | $93.4M | $738.0K | $3.7M |
| Net Change in Cash | $451.7M | $12.7M | $105.7M | $22.0M | $1.8M | $-18.8M | $-4.4M | $-62.9M |
| Free Cash Flow | $-487.0M | $-372.3M | $-202.1M | $-174.6M | $-72.7M | $-124.0M | $-88.4M | $-89.1M |